RE: Bought more14 Sep 2022 11:36
Read through all the previous announcements and you'll see that the company always starts an RNS with 'pleased', 'very pleased'or 'delighted' to announce. When there is bad news it simply says Immuhama 'announces'.
We'll have to wait and see what the implications are from the FDA's response but at best it will mean further delays to the trial.
Remember the original phase III trial that was unsuccessful, this is how the start to the RNS started: 'ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces the results of its pivotal Phase III trial of Lupuzor™, '